Clinical trial NCT01272388: Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study
Official title: Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Aortic Stenosis
Keywords: Aortic valve stenosis
Tadalafil
Phosphodiesterase inhibitors
Hypertension, pulmonary
Hypertrophy, left ventricular
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2011-01-07
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Currently, aortic stenosis (AS) is considered a "surgical disease" with no medical therapy available to improve any clinical outcomes, including symptoms, time to surgery, or long-term survival. Thus far, randomized studies involving statins have not been promising with respect to slowing progressive valve stenosis. Beyond the valve, two common consequences of aortic stenosis are hypertrophic remodeling of the left ventricle (LV) and pulmonary venous hypertension; each of these has been associated with worse heart failure symptoms, increased operative mortality, and worse long-term outcomes. Whether altering LV structural abnormalities, improving LV function, and/or reducing pulmonary artery pressures with medical therapy would improve clinical outcomes in patients with AS has not been tested. Animal models of pressure overload have demonstrated that PDE5 inhibition influences NO-cGMP signaling in the LV and favorably impacts LV structure and function, but this has not been tested in humans with AS. Studies in humans with left-sided heart failure and pulmonary venous hypertension have shown that PDE5 inhibition improves functional capacity and quality of life, but patients with AS were not included in those studies. The investigators hypothesize that PDE5 inhibition with tadalafil will upregulate NO-cGMP signaling, reduce oxidative stress, and have a favorable impact on LV structure and function as well as pulmonary artery pressures and quality of life. In this pilot study, the investigators anticipate that short-term administration of tadalafil to patients with AS will be safe and well-tolerated.

Detailed description: Patients with severe symptomatic AS who will undergo elective aortic valve replacement will be eligible for this randomized, double-blind, placebo-controlled, pilot study. Prior to randomization, subjects will have testing including: 6 minute walk, quality of life questionnaire, blood draw, and an echocardiogram. If an initial monitored dose of tadalafil is tolerated, participants will be randomized 2:1 to tadalafil vs. placebo. After 4 weeks on drug or placebo, subjects will have the same baseline testing repeated. At the time of aortic valve replacement surgery, the aortic valve and a small piece of LV myocardium will be taken for several analyses.

Eligibility criteria: Inclusion Criteria:

* Patients with severe aortic stenosis (AVA \< 1.0 cm2)
* Left ventricular hypertrophy
* EF ≥ 45%
* NYHA functional class ≥ 2
* Ambulatory (able to perform a 6 minute walk test)
* Normal sinus rhythm
* 18 years of age and older
* Able and willing to comply with all the requirements for the study

Exclusion Criteria:

* Need for ongoing nitrate medications
* SBP \< 110mmHg or MAP \< 75mmHg
* Moderately severe or severe mitral regurgitation
* Moderately severe or severe aortic regurgitation
* Creatinine clearance \< 30 mL/min
* Increased risk of priapism
* Retinal or optic nerve problems or unexplained visual disturbance
* If a subject requires ongoing use of an alpha antagonist typically used for benign prostatic hyperplasia (BPH) (prazosin, terazosin, doxazosin, or tamsulosin), SBP \< 120 mmHg or MAP \< 80 mmHg is excluded
* Need for ongoing use of a potent CYP3A inhibitor or inducer (ritonavir, ketoconazole, itraconazole, rifampin)
* Cirrhosis
* Pulmonary fibrosis
* Current or recent (≤ 30 days) acute coronary syndrome
* O2 sat \< 90% on room air
* Females that are pregnant or believe they may be pregnant
* Any condition which the PI determines will place the subject at increased risk or is likely to yield unreliable data
* Unwilling to provide informed consent

Primary outcomes:
measure: Quality of Life as Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)
timeFrame: Baseline and 4 weeks
Secondary outcomes:
measure: 6 Minute Walk Distance
timeFrame: Baseline and 4 weeks
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Brian R. Lindman, MD
role: PRINCIPAL_INVESTIGATOR
References: